Monday, October 18th, 2021

Sir David Amess (1952-2021)

Members of the Alliance for Human Relevant Science were devastated to hear the news of the tragic passing of Sir David Amess on Friday 15th October. Sir David was Vice Chair of the APPG for Human Relevant Science and understood the way in which human health could be improved without the need to use animals. He supported the launch of our Whitepaper in March 2020 and was keen to see change in biomedical science for the benefit of all. Above all, he was approachable, caring and genuinely interested in our cause. His compassion was clear and is reflected in the many tributes now being paid for his charitable work and steadfast dedication to the constituents he represented. He will be sorely missed and our heartfelt condolences go out to his family, friends and colleagues.

Wednesday, September 8th, 2021

Fourth APPG meeting Tuesday 14th September

The fourth APPG on human relevant sciences will be held (virtually) on the Tuesday 14th September 2021 at 4.45 – 6.15pm UK time where we will explore how countries other than the UK have successfully addressed the transition to human relevant approaches and how EU and international animal law and ethics are important factors in this transition.

This final meeting for 2021 for this APPG will be followed by a report of our findings to be published in Nov 2021. Call back here after the meeting to hear what was discussed at the fourth meeting and our plans for the launch of the final report.

Confirmed speakers

Pepik Henneman is co-director and co-founder of Mister Lion, an Amsterdam and Ghent based lab for societal change (Meneer de Leeuw), helpathon specialist and transition management expert. Pepik lectures at the Rotterdam University Erasmus Academie on transition management and social innovation.

After having graduated at the T.U. Delft (1996) Pepik began his career as a petroleum engineer at Shell International Exploration & Production BV. Taken by the concept of sustainability he developed the basis of his vision and practice at Schumacher College (MSc Holistic Science 2001). In 2000, Pepik founds Innovaders consultancy from which he advises organizations on sustainable business. In 2006 he became affiliated to the Dutch Research Institute for Transitions (DRIFT) at Rotterdam Erasmus University where he brings the concepts of transition management into practice. At Meneer de Leeuw, Pepik leads co-creation processes between local government, institutions and citizens on a broad range of societal issues across Europe. His work includes interventions and visionary publications on regional development, urban mobility, living streets, urban climate mitigation, energy saving, sustainable agriculture, youth employment, international cooperation, refugee shelter, social divide, elderly care and citizen participation and more recently animal free innovation and sustainable transitions in the construction sector.

Pepik is the author of Frontrunners in action (Burgermeesterboek, van Gorcum 2012). Frontrunners in action describes a perspective on societal change and proposes a method for local sustainable innovation. ‘In our method we call up on officials of municipalities and departments to radically involve the frontrunners and pioneers to contribute to the development of their region. We call upon leaders of organizations and business to take on the role of regional change agents.’

Mister Lion is a social enterprise
Mister Lion is a social enterprise based in Ghent and Amsterdam, we have intervened in a wide range of societal transitions in Belgium, The Netherlands, France and various other EU countries. We have 15 years of experience in organizing coincidence. We enter into an open dialogue with people in an area, a sector or an organization. We immerse ourselves in each complex social system. Together with our stakeholders we explore new ways of doing, thinking and organizing – and try them out right away.

The way we work
Our clients see the urgency and the potential, our innovation networks explore the possibilities and we listen and look for openings. We follow the energy and discover new organizing ideas. We help our clients innovate and become more effective in accomplishing their societal mission. We ask for space and freedom to look afresh and find suitable ways to achieve results.

Animal Free Innovation
Mister Lion was asked in 2014 to lead round table discussions for the think tank on alternative financing for animal-free testing from a transition perspective, via the co-creative ‘temporary innovation network’ approach. From these conversations, the first transition sketch of the animal testing regime emerged. This sketch is included in the publication In Transitie!, together with the recommendation to continue the ‘temporary innovation networks’ approach. At the end of 2017, Mister Lion was asked by the Ministry of LNV to help set up the temporary renewal networks strategy, which forms the basis of the current TPI programme. Mister Lion was then challenged to show how the concept of temporary innovation networks can be successfully put into practice. Mister Lion organised and led the Innovative Health Research network. At the beginning of 2019, this new network presented its progress report with clarification, results and challenges. The network also introduced the Helpathon as a new innovation protocol. Since then Mister Lions co-organized five successful TPI Helpathons.

Prof. dr. Sue Gibbs is Chair in skin and mucosa regenerative medicine at both Amsterdam University Medical Center and Academic Center for Dentistry Amsterdam (ACTA). Her entire career has focused on human skin and mucosa biology, in particular in animal alternative methods to develop novel therapeutic strategies for treating and preventing human disease. In vitro models are currently implemented for risk assessment and testing mode of action of compounds and novel actives, in collaboration with industry. In 2015, she received the national ‘’Daring in the Lab’’ prize by the Dutch Animal Protection society. Recently, her research has extended into the field of hair follicles and importantly ‘’organ-on-a-chip’’, in particular immune competent ‘’skin-, melanoma-, lymph node- and gut- on-a-chip’’. These models have the potential to provide a personalized medicine approach to treating human disease. She joined the TPI network in 2018 and helped initiate the Helpathon to assist scientists willing to transition to animal free innovations. The Helpathon team won the international LUSH prize in 2020 enabling the funding of Helpathons in 2021.

David Thomas is a solicitor. He has acted for nearly all the major animal protection organisations in the UK (and beyond) and is highly experienced in EU and international animal law, including trade law. He has also acted extensively in human rights cases (which can be relevant to animal protection law), much of it again international, and public law more generally. He is a fellow of the Oxford Centre for Animal Ethics, a former chair of the RSPCA (currently a trustee) and a former director of Cruelty Free International and Compassion in World Farming. He has written extensively about animal protection law and ethics and taken part in numerous presentations, debates and media appearances. He gave oral evidence to the Burns Inquiry on hunting and has given oral testimony to several parliamentary committees and a Royal Commission as well as holding countless meetings with ministers and officials. He has been a member of European Commission and UK government panels and is an experienced teacher of law.

 

 

Friday, July 30th, 2021

The Alliance for Human Relevant Science Offers to Support a Governmental Review of Animal Testing for Medicines in the UK

The Alliance for Human Relevant Science, an inclusive collaboration of like-minded companies, organisations and individuals working together to support and promote human relevant research for improved health, welcomes reports that the Government will review the use of animals in the development of medicines. Data obtained in animals is of limited relevance to humans and has not enabled development of effective treatments for many life-threatening and debilitating diseases.  There is an urgent need to transition from reliance on animal procedures to use of methods that focus directly on human biology which can provide more useful insights into human diseases and disease treatments. The opportunity provided by methods that use human organs, tissues and cells grown in the lab is a step forward in this transition and has already been highlighted in the Alliance’s series of APPG meetings this year.

Many of our members have worked with pharmaceutical companies, regulators, and academics to address issues raised in making this transition, and a wealth of data supporting the benefits of the new approach methodologies (NAMs) is available. There may be apprehension surrounding this move but we offer our expertise and advice to officials carrying out this review on how this can be done in a measured, responsible and fully informed way.

 

Friday, April 23rd, 2021

Third APPG on human relevant science

The third APPG on human relevant sciences will be held (virtually) on the Wednesday 12th May 2021 at 3 – 4.30pm UK time where we will continue to gather evidence of funding sources and gaps for human relevant approaches in the UK.

Our final meeting will focus on defining changes required in regulations (Sept 2021) in order for these methods to be more widely adopted. A report of our findings will be available in Nov 2021. Call back here after the 12th May 2021 to hear what was discussed at the third meeting.

Click here for more info

Wednesday, January 13th, 2021

Next APPG meeting date confirmed.

Our second APPG meeting will be held (virtually) on Tuesday 9th February at 4pm UK time, where we will start the process of examining whether the current regulatory framework is designed to promote the implementation and adoption of human relevant technologies in the  UK.

Future meetings will focus on defining changes required in funding (May 2021) and regulations (Sept 2021) in order for these methods to be more widely adopted. A report of our findings will be available in Nov 2021. Call back here after the 9th February 2021 to hear what was discussed at the second meeting!

Click here for more info.

Monday, January 11th, 2021

CN Bio’s PhysioMimix™ technology receives FDA recognition

Alliance member CN Bio announces how a joint publication with the FDA demonstrates the advantages of their PhysioMimix™ in drug safety and metabolism applications, over standard techniques. This represents the first co-published, peer-reviewed article between a microphysiological system provider and a regulator:

Tuesday, October 6th, 2020

PRESS RELEASE New Parliamentary group calls for human relevant science moonshot

Tuesday 6 October, London: A new All-Party Parliamentary Group today held its first AGM with the aim of accelerating the development and uptake of human relevant life sciences in the UK.

The APPG on Human Relevant Science held its first meeting remotely on Tuesday 6 October, where the group outlined its priorities.

The APPG will be a discussion forum for politicians, the human relevant life sciences sector, third sector groups, scientists and stakeholders to promote new approach methodologies that provide unique insights into human biology, transform our ability to understand human disease and can develop effective new medicines more quickly and without the use of animals.

Its programme will cover the themes of strategic funding to incentivise the development and use of human relevant methods and technologies, and incorporation of human relevant methods into regulatory guidelines on medicines development.

The APPG’s statement of purpose is to bring together MPs and Peers of all parties to accelerate the development and uptake of human relevant life sciences in the UK.

Replacing poorly performing animal tests with innovative human relevant new approach methodologies will directly benefit the UK science base and enhance the efficiency and profitability of industries that make vital contributions to the UK economy.

Speaking at the launch, the APPG’s Chair, Labour MP Grahame Morris, said, “I am delighted to Chair the new All-Party Parliamentary Group on Human Relevant Science. The COVID-19 pandemic has demonstrated that the current approach to developing new treatments is simply not fast enough to meet humanity’s needs. We urgently need a moonshot to transition to new approach methodologies which promise to deliver safer and more effective medicines, more quickly and at less cost.”

APPG Vice Chair Conservative MP Sir David Amess said, “I am thrilled to be Vice Chair of the new All-Party Parliamentary Group on Human Relevant Science. With the cancellation of the Autumn Budget, the Government now has more time to think about what it can do to provide much-needed financial support to boost growth in the human relevant life sciences sector and enable the UK to remain an innovative science superpower.

“As the country seeks a COVID-19 vaccine, this is the perfect time for parliamentarians to take seriously the growing evidence in favour of the pioneering human relevant medical research techniques that are replacing the outdated use of animals.”

The Alliance for Human Relevant Science acts as the group’s secretariat.

ENDS

For more information please contact the Cruelty Free International media office;

email: media@crueltyfreeinternational.org  or telephone: +44 (0) 7590055 206.

NOTES

About the Alliance for Human Relevant Science

The Alliance for Human Relevant Science is an inclusive collaboration of like-minded companies, organisations and individuals, working together to show how significant advances in science and technology can deliver new methods based on human biology, with the potential to improve the safety of medicines and other chemicals.

 

Tuesday, July 14th, 2020

A CALL TO ACCELERATE HUMAN-FOCUSSED MEDICAL RESEARCH

An open letter to:

International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
The International Coalition of Medicines Regulatory Authorities
European Medicines Agency
European Directorate for the Quality of Medicines and Healthcare
European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM)
Home Office
Department of Health and Social Care
Department for Business, Energy & Industrial Strategy
Medicines & Healthcare products Regulatory Agency
National Institute for Health and Care Excellence (NICE)

We are calling for a change of mindset and a clear timetable for regulatory change to enable accelerated development of medicines which are likely to be safer, more effective and cheaper, without the use of animals. Investment in human relevant science offers a golden opportunity to revitalise medical research, save money, create wealth and improve public health.

We find ourselves in a time of global health emergency, one that will challenge our healthcare, social fabric and economy for years to come. Hard choices today have been borne out of great and immediate need. Yet there are patterns emerging in the scientific response that will have far reaching consequences for how we progress medical science in the future.

 

Continue reading

Friday, March 20th, 2020

WHITEPAPER LAUNCH

On Tuesday 10th March 2020, Grahame Morris MP hosted the launch of our new whitepaper “Accelerating the Growth of Human Relevant Life Sciences in the United Kingdom” at Portcullis House, Westminster, London. MPs and scientists were able to discuss how significant advances in science and technology have delivered new methods based on human tissues and cells and have the potential to improve the prediction of human toxicities caused by medicines and other chemicals. Read the full whitepaper and a summary here.

Tuesday, March 10th, 2020

Accelerating the Growth of Human Relevant Life Sciences in the United Kingdom

The Alliance for Human Relevant Science, calls for a fresh approach to biomedical research and drug discovery.

New approach methodologies (NAMs) that are human relevant have the potential to improve the efficiency of drug research and development and to deliver safer, cheaper and more effective medicines to patients.

In the released White paper ‘Accelerating the Growth of Human Relevant Life Sciences in the United Kingdom’, the Alliance calls for support from the Government to assist businesses in the transition to NAMs by providing supportive infrastructure, strategic funding, education, collaboration between industries and regulatory engagement.

There is an opportunity for the UK to be a world leader in developing and evaluating NAMs. Investment in human relevant methods is good for both business and public health.

Read the White Paper summary document
Read the full paper